ResearcherUniversity of OxfordNo recent work listed

Remko Prevo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5196-0552; OpenAlex author ID A5041976085. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2012: 1 paper

Papers 1

The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy. Co-author DOI 10.4161/cbt.21093 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Ruth J. Muschel · 1 shared paper, 2012 · strength 0.03
- Paper The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy. DOI 10.4161/cbt.21093 ↗
Thomas Baptist Brunner · 1 shared paper, 2012 · strength 0.03
- Paper The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy. DOI 10.4161/cbt.21093 ↗
Emmanouil Fokas · 1 shared paper, 2012 · strength 0.03
- Paper The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy. DOI 10.4161/cbt.21093 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.